Pilot Study of Vitamin D Supplementation in Heart Failure

• Status: Completed
• Trial end date: 2012-07-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine if the methods are feasible for a larger clinical trial.The study will examine the relationship between vitamin D status, quality of life, pain and walking distance of individuals living with heart failure.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Fraser Health
• Treatments: Cholecalciferol; Ergocalciferols; Vitamin D; Vitamins

Criteria

Inclusion Criteria:

• 65 years of age or older

• New York Heart Association functional Class II or III symptoms

• Ability to communicate in English or through a translator

• Competent to sign the informed consent

Exclusion Criteria:

• Co-morbidity that would negatively impact quality of life (e.g. severe arthritis, or fibromyalgia)

• Co-morbidity that would negatively impact vitamin D metabolism (glomerular filtration rate-15-29%, significant liver dysfunction

• On a pharmaceutical agent that could lower Vitamin D levels (e.g. glucocorticoids, anticonvulsants)

• Taking >600 IU vitamin D (cholecalciferol or ergocalciferol) daily

• Moderate or severe cognitive impairment

• Contraindication to vitamin D supplementation: history of hypercalcemia or conditions that increase the risk of hypercalcemia (sarcoidosis, tuberculosis or lymphoma)

• Wheelchair bound (ambulation is a component of the QOL questionnaire